NEUCA S.A. AI Stock Analysis
NEUCA S.A. (0MJR) AI Stock Analysis
NEUCA S.A.
(LSE:0MJR)
No summary available
NEUCA S.A. (0MJR) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- PLN 3.25B
- Dividend Yield
- 2.56%
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- 16.4
- Beta (1Y)
- ―
- Revenue Growth
- 8.42%
- EPS Growth
- 43.47%
- Country
- UK
- Employees
- 5,004
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Distribution
NEUCA S.A. Business Overview & Revenue Model
Company Description
NEUCA S.A., headquartered in Torun, Poland, specializes in supplying pharmaceutical products to pharmacies and healthcare facilities throughout the country. The firm structures its business around distinct segments: wholesale pharmaceutical distribut...
NEUCA S.A. Peers Comparison
Overall Rating
PL:BIO45Neutral
PL:CLN42Neutral
PL:MAB41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 45Neutral | PLN 297.09M | -25.18 | -1.97% | ― | -15.67% | -307.60% | |
| 42Neutral | PLN 830.24M | 7.33 | 24.89% | ― | ― | ― | |
| 41Neutral | PLN 151.76M | -2.68 | -124.37% | ― | 11.57% | 4.35% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:0MJR | NEUCA S.A. | 760.00 | 0.00 | 0.00% | |
| PL:SVE | Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. | 2.68 | -1.35 | -33.42% | |
| PL:CLN | Celon Pharma SA | 15.40 | -6.10 | -28.37% | |
| PL:BIO | BIOTON S.A. | 3.46 | -0.53 | -13.28% | |
| PL:MRC | Mercator Medical SA | 56.50 | 18.05 | 46.96% | |
| PL:MAB | Mabion SA | 9.39 | 1.72 | 22.43% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
